Fairvalue-Calculator Fairvalue-Calculator
EN DE

Surgery Partners, Inc (SGRY) Fair Value & Analysis

Healthcare · US · Market cap $1.9B

Price$15.22
Fair Value$21.69
Upside+42.5%
Quality80/100
Evidence: Medium Range $16.46 – $34.35

Analysis

Surgery Partners, Inc (SGRY) currently trades at $15.22, while our model-based Fair Value estimate is $21.69 — implying the stock looks roughly 42.5% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) -73% Fresenius SE (FSNUY) -27% 5225 (5225) -70% IHHHF (IHHHF) -26% Tenet Healthcare Corporation (THC) +74% Rede D'Or São Luiz S.A (RDOR3) -7%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.